WO2001097824A3 - Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae - Google Patents

Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae Download PDF

Info

Publication number
WO2001097824A3
WO2001097824A3 PCT/EP2001/006981 EP0106981W WO0197824A3 WO 2001097824 A3 WO2001097824 A3 WO 2001097824A3 EP 0106981 W EP0106981 W EP 0106981W WO 0197824 A3 WO0197824 A3 WO 0197824A3
Authority
WO
WIPO (PCT)
Prior art keywords
flaviviridae
treating
viruses
family
phyllanthus
Prior art date
Application number
PCT/EP2001/006981
Other languages
English (en)
French (fr)
Other versions
WO2001097824A2 (de
Inventor
Keudell Christoph Von
Der Giessen Robert H M Van
Original Assignee
Cmi Ag
Keudell Christoph Von
Giessen Robert H M V D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cmi Ag, Keudell Christoph Von, Giessen Robert H M V D filed Critical Cmi Ag
Priority to US10/311,961 priority Critical patent/US20040028754A1/en
Priority to CA002413331A priority patent/CA2413331A1/en
Priority to AU2001269082A priority patent/AU2001269082A1/en
Priority to EP01947381A priority patent/EP1294387A2/de
Publication of WO2001097824A2 publication Critical patent/WO2001097824A2/de
Publication of WO2001097824A3 publication Critical patent/WO2001097824A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft daher die Verwendung von einem oder mehreren Phyllanthusbestanteil(en) oder daraus gewonnenen Stoffen oder Stoffgemischen zur Prävention oder Behandlung von Infektionskrankheiten, die durch Viren der Familie der Flaviviridae hervorgerufen werden oder an deren Entwicklung oder Progression Viren der Familie der Flaviviridae beteiligt sind. Weiterhin betrifft die Verwendung von einem oder mehreren Phyllanthusbestandteil(en) oder daraus gewonnenen Stoffen oder Stoffgemischen zur Herstellung eines Arzneimittels zur Prävention oder Behandlung von Infektionskrankheiten, die durch Viren der Familie der Flaviviridae hervorgerufen werden oder an deren Entwicklung oder Progression Viren der Familie der Flaviviridae beteiligt sind. Ein bevorzugtes Virus ist das Hepatitis C Virus.
PCT/EP2001/006981 2000-06-20 2001-06-20 Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae WO2001097824A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/311,961 US20040028754A1 (en) 2000-06-20 2001-06-20 Use of phyllanthus component for the treatment or prophylaxis of infections triggered by flaviviridae
CA002413331A CA2413331A1 (en) 2000-06-20 2001-06-20 Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
AU2001269082A AU2001269082A1 (en) 2000-06-20 2001-06-20 Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
EP01947381A EP1294387A2 (de) 2000-06-20 2001-06-20 Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10030139A DE10030139A1 (de) 2000-06-20 2000-06-20 Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae
DE10030139.8 2000-06-20

Publications (2)

Publication Number Publication Date
WO2001097824A2 WO2001097824A2 (de) 2001-12-27
WO2001097824A3 true WO2001097824A3 (de) 2002-05-10

Family

ID=7646244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006981 WO2001097824A2 (de) 2000-06-20 2001-06-20 Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae

Country Status (6)

Country Link
US (2) US20040028754A1 (de)
EP (1) EP1294387A2 (de)
AU (1) AU2001269082A1 (de)
CA (1) CA2413331A1 (de)
DE (1) DE10030139A1 (de)
WO (1) WO2001097824A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213996A1 (en) 2000-10-06 2002-04-22 Cmi-Centers For Medical Innovation Ag Method for producing phyllanthus extracts
DE10120627A1 (de) * 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
WO2007044468A2 (en) * 2005-10-05 2007-04-19 The Cbr Institute For Biomedical Research, Inc. Method to treat flavivirus infection with sirna
US20070196381A1 (en) * 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
KR101105889B1 (ko) 2009-09-29 2012-01-16 주식회사 바이오엔그린텍 생약 복합 추출물을 유효성분으로 포함하는 가축의 설사 예방 및 치료용 조성물 및 이의 제조방법
US20130122119A1 (en) * 2011-11-01 2013-05-16 Natreon, Inc. Phyllanthus amarus compositions and method of extracting same
KR101537468B1 (ko) * 2014-01-16 2015-07-16 성균관대학교산학협력단 필란두스 액시더스 추출물을 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약학적 조성물
CN111529565A (zh) * 2020-06-11 2020-08-14 广东盛普生命科技有限公司 一种抗流感病毒的制剂及其制备方法和应用
CN111494452A (zh) * 2020-06-11 2020-08-07 广东盛普生命科技有限公司 一种眼用药剂及其制备方法
CN111529566A (zh) * 2020-06-11 2020-08-14 广东盛普生命科技有限公司 一种抗病毒喷剂及其制备方法和应用
CN111588744A (zh) * 2020-06-11 2020-08-28 广东盛普生命科技有限公司 一种抗病毒组合物与口服液及其制备方法和应用
EP3954379A1 (de) * 2020-08-12 2022-02-16 HFM - Hybrid Fusion Medicals, GmbH Zusammensetzungen mit phyllanthus-extrakt zur verwendung in der behandlung oder vorbeugung einer sars-cov-2-infektion und/oder mindestens eines symptoms von covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
WO2000061161A2 (en) * 1999-04-12 2000-10-19 University Of Madras A pharmaceutical formulation useful for the treatment of hepatitis b, hepatitis c and other viral infections of the liver and a process for its preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US161477A (en) * 1875-03-30 Improvement in curtain-fixtures
US33275A (en) * 1861-09-10 Improved pipe-joi-nt
US4388457A (en) * 1982-02-11 1983-06-14 University Patents, Inc. Phyllanthostatin compounds
US4937074A (en) * 1988-03-29 1990-06-26 Fox Chase Cancer Center Method of treating retrovirus infection
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5529778A (en) * 1994-09-13 1996-06-25 Rohatgi; Surendra Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US5571441A (en) * 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback
US6136316A (en) * 1996-04-17 2000-10-24 Dabur Research Foundation Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
DE19919585A1 (de) * 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
WO2000061161A2 (en) * 1999-04-12 2000-10-19 University Of Madras A pharmaceutical formulation useful for the treatment of hepatitis b, hepatitis c and other viral infections of the liver and a process for its preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAWRENCE S P: "ADVANCES IN THE TREATMENT OF HEPATITIS C", ADVANCES IN INTERNAL MEDICINE, YEAR BOOK MEDICAL PUBLISHERS, CHICAGO, IL,, US, vol. 45, 2000, pages 65 - 105, XP000965224, ISSN: 0065-2822 *

Also Published As

Publication number Publication date
CA2413331A1 (en) 2001-12-27
AU2001269082A1 (en) 2002-01-02
DE10030139A1 (de) 2002-01-10
US20040028754A1 (en) 2004-02-12
US20020054921A1 (en) 2002-05-09
WO2001097824A2 (de) 2001-12-27
EP1294387A2 (de) 2003-03-26

Similar Documents

Publication Publication Date Title
WO2003053349A3 (en) Inhibitors of hepatitis c virus
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
EA200700243A1 (ru) Способы лечения гепатита с
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
WO2001097824A3 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A8 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
SI1404347T1 (sl) 4'-substituirani nukleozidi za zdravljenje bolezni posredovanih z virusom hepatitisa c
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
CY1112042T1 (el) Ιικοι αναστολεις
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2004032827A3 (en) Hepatitis c virus inhibitors
PL376409A1 (en) Composition for the treatment of infection by flaviviridae viruses
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
EA200700718A1 (ru) Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2413331

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001947381

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001947381

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10311961

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001947381

Country of ref document: EP